Ludwig Institute for Cancer Research
The Ludwig Institute for Cancer Research is a global non profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for human benefit.
Program Highlights
Vascular Endothelial Growth Factors
For over seven years, LICR has coordinated and supported a global Program to research angiogenesis and lymphangiogenesis with the aim of developing therapies that could target both processes. The efforts of the Program investigators, drawn from the Melbourne, Stockholm and Uppsala Branches as well as Affiliates in Helsinki and Kuopio (Finland), have identified four of the five known vascular endothelial growth factors (VEGF-B, VEGF-C, VEGF-D and VEGF-E) and two of the four known platelet-derived growth factors (PDGF-C and PDGF-D) as well as a novel receptor, VEGF receptor-3 (VEGFR-3). More »
News
Jeanne Tie, MD, from the Melbourne Branch of the international Ludwig Institute for Cancer Research was presented with The Bradley Stuart Beller Merit Award at an awards ceremony held at the American Society of Clinical Oncology (ASCO) annual meeting in Florida.
Researchers from the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine have uncovered a remarkable property of the contractile ring, a structure required for cell division. Understanding how the contractile ring works to divide the cell may facilitate development of therapies to prevent uncontrolled cell division in cancer.